Friday, April 1, 2016
Quintiles has been named the Best CRO in Asia at the 2016 BioPharma Asia Industry Awards, winning the honor for the fourth time in the event’s six-year history. The award goes to the CRO that best demonstrates an ongoing commitment to improving clinical research services in Asia and reducing lead times for customers.
Dr. Zbigniew Markowski has stepped down, for personal and family reasons, from his positions as chief executive officer of Helix BioPharma and chairman of Helix Polska. Helix BioPharma is a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer. Dr. Sven Rohmann will replace Markowski, effective immediately.
Parexel International, a global biopharmaceutical services organization, has announced that Forbes named the company to the magazine’s America’s “Best Employers” list for 2016. The list features the top 500 U.S. employers with more than 5,000 employees as rated by 30,000 employees in an independent survey.
The Biotechnology Innovation Organization (BIO) has named Dr. J. Craig Venter as the recipient of its 2016 George Washington Carver Award for innovation in industrial biotechnology. The award honors the legacy of George Washington Carver, who was one of the founding fathers of the chemurgy movement, a branch of applied chemistry focused on manufacturing industrial products from raw agricultural materials. Industrial biotechnology is the modern-day equivalent of Carver’s vision for chemurgy, and the annual award honors an individual for carrying on Carver’s legacy.
In the publication of its 2015 Annual Report to shareholders, GlaxoSmithKline has announced that Sir Andrew Witty, CEO, has indicated to the board his intention to retire from the company in early 2017. The board has agreed that he will retire on March 31. The board will now conduct a formal search for a successor and will consider internal and external candidates for the role.
INC Research, a, global phase I to IV CRO, has appointed Judith Ng-Cashin, M.D., as chief scientific officer. Dr. Ng-Cashin will lead the integration of the Company’s industry-recognized therapeutic and medical/scientific expertise for phase I to IV clinical trials. She will be responsible for scientific, medical and ethical governance matters, including collaboration with key medical and scientific stakeholders to strengthen INC’s position as a collaborative partner to clinical practice, sponsor and academic organizations.